Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction

NEW TAIPEI CITY, Jan. 23, 2024 /PRNewswire/ — Caliway Biopharmaceuticals (Caliway) announces that Australian Bellberry HREC has approved Caliway’s application to initiate CBL-514’s Pivotal Phase 3 study (CBL-0301 Phase 3) for subcutaneous fat reduction. “We are all delighted to see…